Public health impact and cost-effectiveness of 15-valent pneumococcal conjugate vaccine use among the pediatric population of the United States-Reference-Cited by-同舟云学术

Public health impact and cost-effectiveness of 15-valent pneumococcal conjugate vaccine use among the pediatric population of the United States

Published:2023-05 Issue:18 Volume:41 Page:2914-2921
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Prasad Namrata^ORCID,Stoecker Charles^ORCID,Xing Wei,Cho Bo-Hyun^ORCID,Leidner Andrew J.^ORCID,Kobayashi Miwako^ORCID

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference45 articles.

1. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000;49:1-35.

2. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine;Pilishvili;J Infect Dis,2010

3. Incidence of acute otitis media in children in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998–2018;Hu;BMC Infect Dis,2022

4. Health Care Utilization for Pneumonia in Young Children after Routine Pneumococcal Conjugate Vaccine Use in the United States;Zhou;Arch Pediatr Adolesc Med,2007

5. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance;Moore;Lancet Infect Dis,2015

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Health-economic burden attributable to novel serotypes in candidate 24- and 31-valent pneumococcal conjugate vaccines;Vaccine;2024-12

2. Health-economic burden attributable to novel serotypes in candidate 24- and 31-valent pneumococcal conjugate vaccines;2024-04-12

3. Outpatient Visits and Antibiotic Use Due to Higher-Valency Pneumococcal Vaccine Serotypes;The Journal of Infectious Diseases;2024-03-18

4. Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants;Vaccine;2024-01

5. Pneumococcal Transmission Dynamics During the Use of a Pediatric 13-Valent Pneumococcal Conjugate Vaccine in Canada;SSRN Electronic Journal;2024